According to filings with the U.S. Securities and Exchange Commission, CRISPRQC is raising up to $10,000,000.00 in new funding. Sources indicate that as part of senior management President, Ross Bundy played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CRISPRQC
CRISPR QCs Mission is to empower scientists using CRISPR to solve the worlds great challenges by providing key cornerstones of information and insight fundamental to realizing the full potential of CRISPR. CRISPR QC is more than just quality control of your gene edits. We offer you the knowledge and data to improve your CRISPR/Cas9 assay designs. We assist researchers, scientists, and clinicians in accelerating the development of CRISPR/Cas9 based genomic therapies by providing a platform of certainty through end-to-end advanced analytics of CRISPR/Cas9 designs to facilitate on-target data-driven decisions. CRISPR/Cas9 techniques are used as a quicker, more precise method to edit animal DNA. CRISPR QC provides the insights needed to optimize experimental designs and to execute them with confidence. Plant genomics benefits from CRISPR/Cas9 gene-editing methods to improve traits such as disease resistance, yield, and drought tolerance. CRISPR QC equips researchers with the data needed to probe every permutation in an experimental design. CRISPR QC understands researchers and scientists desire to know, understand, and obtain wisdom. With CRISPR-CHIP as the foundation of our CRISPR/Cas9 gene-editing quality control process we have a path for knowledge seekers to pursue.

To learn more about CRISPRQC, visit http://www.crisprqc.com/

Contact:
Ross Bundy, President
858-444-0037
https://www.linkedin.com/in/ross-bundy-36874310/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.